Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Heparin Anticoagulation to Improve Outcomes in Septic Shock (HALO International Phase II RCT)
2018-003726-93Phase 2Completed
- Sponsor
- Hellenic Institute for the Study of Sepsis
- Start
- Apr 2019
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised trial of heparin in septic shock and sepsis (2 arms), sponsored by Hellenic Institute for the Study of Sepsis. Primary endpoint: Vasopressor-free days. Started Apr 2019; status: completed.
02
Drugs
heparin
03
Conditions
septic shocksepsis
Beyond the preview
Go deeper on 2018-003726-93.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003726-93.